Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system

• Asıl Yazarlar: Jun Shen (Yazar), Pingli Luo (Yazar), Jianmei Xu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: SAGE Publishing, 2024-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are targeted therapies designed to selectively block CDK4/6, crucial regulators of the cell cycle. These inhibitors play a pivotal role in restoring cell cycle control, particularly in breast cancer cases marked by abnormal CDK regulat...